Agilent's PD-L1 test gets OK for head, neck cancer in Europe

LabPulse.com staff writers
Nov 21, 2019
2019 11 22 18 03 1711 Eu Flag 400

Agilent Technologies' programmed cell death ligand 1 (PD-L1) immunohistochemistry (IHC) 22C3 pharmDx assay has been labeled for use in patients with head and neck squamous cell carcinoma (HNSCC) in the European Union.

The assay is approved for use as a companion diagnostic with the checkpoint inhibitor pembrolizumab (Keytruda, Merck), the company said in a statement. Keytruda is approved as a monotherapy or in combination with chemotherapy for the first-line treatment of metastatic or unresectable recurrent HNSCC in adults whose tumors express PD-L1 with a combined positive score of at least 1.

Head and neck squamous cell carcinoma is the seventh most common type of cancer in the world, according to Agilent. In Europe, approximately 170,000 new head and neck cancer cases are diagnosed each year.

Latest in Head and Neck Cancer
Scientists Collaborate Team Social
Nucleai, Adlai Nortye collaborate on biomarkers for clinical trials
May 31, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
2017 09 14 23 05 1167 Cancer Cell 400
Viome launches early detection test for oral and throat cancers
August 3, 2022
2020 02 05 22 27 6689 Head Neck 400
Sysmex Inostics touts liquid biopsy findings at ASCO
June 3, 2021
Related Stories
Business Financial Results Social
Financial Results
Agilent Technologies Q1 revenues rise 5% on strength in life sciences, applied markets
2022 06 09 19 27 4366 Cell Gene Therapy Dna 400
Validation
Oxford BioDynamics launching oncology test in the U.K.
2020 09 08 18 51 2374 Business Handshake Meeting 400
Agreement
Thomas Scientific inks distribution deal with Agilent
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Head and Neck Cancer
Nucleai, Adlai Nortye collaborate on biomarkers for clinical trials
By LabPulse.com staff writers
The partnership will combine Nucleai's expertise in extracting and analyzing the quantitative spatial features of pathology images and Adlai Nortye's expertise in drug development and immunotherapy.
May 31, 2023
Scientists Collaborate Team Social
Mayo Clinic, Naveris collaborate to evaluate HPV DNA test in clinical trial
By LabPulse.com staff writers
The test is being developed with the aim of aiding treatment selection for patients with HPV-driven head and neck cancer.
April 13, 2023
Head Neck Social
Viome launches early detection test for oral and throat cancers
By LabPulse.com staff writers
The test leverages mRNA technology and an artificial intelligence platform to detect biomarkers for oral and throat cancer with 95% specificity and 90% sensitivity rates, the firm said.
August 3, 2022
2017 09 14 23 05 1167 Cancer Cell 400
Sysmex Inostics touts liquid biopsy findings at ASCO
By LabPulse.com staff writers
The featured data will show how the company's SafeSEQ cfHPV-DNA Test (HPV-SEQ) detects cell-free HPV DNA, enabling monitoring for patients with HPV and oropharyngeal squamous cell carcinoma (OPSCC), a type of head and neck cancer.
June 3, 2021
2020 02 05 22 27 6689 Head Neck 400
Google reports pathology AI helps predict survival in cancer patients
By Emily Hayes
The deep-learning system was developed and tested using histopathology slides for patients with 10 cancer types -- including bladder cancer, invasive breast cancer, and head and neck squamous cell carcinoma -- drawing from publicly available data from the Cancer Genome Atlas (TCGA) program.
June 17, 2020
2020 06 16 21 12 7935 Artificial Intelligence Ai Hand 400
Naveris blood test spots recurrence of HPV cancers
By LabPulse.com staff writers
The test is designed to identify tumor-modified viral HPV DNA. The prospective study, conducted by lead author Dr. Bhisham Chera of the University of North Carolina School of Medicine and colleagues, included 115 patients treated for HPV-related head and neck cancers who were tracked for recurrence for up to 3.5 years with imaging and fiber-optic nasopharyngeal endoscopy. The patients had the blood test before and during treatment and at post-treatment follow-up visits.
February 5, 2020
2020 02 05 22 27 6689 Head Neck 400
Sysmex offers SafeSeq breast, head and neck cancer panels
By LabPulse.com staff writers
SafeSeq liquid biopsy delivers sensitivity down to five mutant molecules among 10,000 wildtype copies, or 0.05% mutant allele frequency, the company said.
September 29, 2019
2019 07 27 00 04 3609 Breast Cancer Cell 400
With LabCorp's lead, Mount Sinai dives into digital pathology
By LabPulse.com staff writers
Philips Healthcare's IntelliSite Pathology Solution software is now being deployed across Mount Sinai's eight hospitals, using LabCorp's experience with the product as a guide for implementation, building on prior collaborative efforts. The plan is to enable Mount Sinai specialists to provide real-time pathology interpretations in the New York metropolitan area, with an initial focus on prostate tumors and other genitourinary malignancies and head and neck cancer. Mount Sinai pathologists will also provide national teleconsulting work for LabCorp's Dianon specialty pathology lab in the future.
June 17, 2019
2019 06 18 21 38 5865 Lab Microscope Pathology 400
Page 1 of 1